about
Locally efficient estimation of the quality-adjusted lifetime distribution with right-censored data and covariates.Simultaneous analysis of quality of life and survival data.Using inverse-weighting in cost-effectiveness analysis with censored data.Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic ModelingVariance and sample size calculations in quality-of-life--adjusted survival analysis (Q-TWiST).Bayesian Regression Models for the Quality Adjusted Lifetime Data with Zero Time Duration Health StatesPredictors of surgical outcomes.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches.Patient reported outcomes as endpoints in medical research.Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder.Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneInfliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialQuality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.Quality-of-life concerns in lung cancer patients.Quality of life and supportive care for patients with metastatic renal cell carcinoma.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Decision analysis in the clinical neurosciences: a systematic review of the literature.Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer.Nonparametric inference for time-dependent incremental cost-effectiveness ratios.Estimating the cumulative mean function for history process with time-dependent covariates and censoring mechanism.Impact of nine chronic conditions for US adults aged 65 years and older: an application of a hybrid estimator of quality-adjusted life years throughout remainder of lifetime.Nonparametric inference for the joint distribution of recurrent marked variables and recurrent survival time.Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.Evaluating Utility Measurement from Recurrent Marker Processes in the Presence of Competing Terminal Events.The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China.Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer.Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma.Quality of life assessment in clinical cancer research.Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.Item response models for joint analysis of quality of life and survival.Quality adjusted survival analysis with repeated quality of life measures.Testing equality of survival functions of quality-adjusted lifetime.Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer.Live long, live well: quantifying the health of heterogeneous populations.
P2860
Q30650154-50AB7298-A4EB-46B1-AAE5-6B3BA54E3431Q30683556-3A940447-E156-453C-BDBE-7A239D01A53BQ30760278-81209B16-713E-4BC9-8094-52A86FCE34FBQ33656552-B314E28B-CE86-4092-9C57-8ECAB0C55005Q33656740-5C0E2286-44CC-4ECC-952B-3DCC7496C025Q33900375-7A77BC5F-E779-4896-B368-B0EAA2EB9FA3Q34266055-D8BF4200-4CC6-453A-B5E1-4A09DF64DC80Q34631386-7A326551-BD5A-44B4-95C4-92E9F256D0CCQ35034768-2CC3382B-F9DD-4935-8508-D7BA8819E7D0Q35049849-E73B0AE0-B2BB-4C02-AC67-94273B8A6D01Q35739677-C3C054DD-1488-44CD-8DAF-A4C284F657E1Q36069919-ABAD794F-49D0-42BC-9AF4-E3FF877CAB40Q36859184-BB41FAED-7AD2-404E-8561-1FE530193E4DQ37003295-8A892DEA-BE18-4ECD-92F4-6A81C1499CFAQ37152795-74938425-5A01-4418-B4AB-033BD548E2BFQ37196938-A83753E1-06C8-4D9D-ABB4-207860DBEEE1Q37347493-9387BFAA-7AF5-48CB-BA43-AD8D990DC086Q37820679-0F53C7E9-6AA3-4D83-9483-4C95373DFA46Q38017587-0E60ED48-FF04-4C30-9FD0-47AB30A2A556Q38020248-8F67B237-CB19-410F-BC7B-5D700BD9ED3FQ38166824-1E179927-DA84-4021-9B9E-94746D96AF76Q38219342-C0F392E9-1BA2-4325-91E0-82A8635FFB9FQ38980612-A31FE8E1-874D-4A41-8501-50964342D47AQ39738293-4A5B13A0-00B2-4CE1-8F1B-FF74B07E29FDQ40092967-49BFEF94-98C2-42AC-9804-12499A8211F4Q40481622-F5CC24CF-468D-471A-B51C-0749B7CE5D32Q41476938-EA9954DA-3073-465D-A4B8-35CA7CD584DBQ41674581-6C951B0B-E778-454D-8205-3F8F56645027Q41822418-C02FE9DD-E6BB-44F3-9E40-7C1F27CDF5A9Q41903983-D2A9C06E-E64B-4B2F-8A30-5BAE5D0E6B8FQ42039424-F314299A-A254-487F-BC47-662A0A294A28Q42590178-6B0BDE65-E399-4F87-A9BD-32F548B60A83Q43021549-28DD783B-57C9-4000-B5A0-9F7945F31E6BQ43848309-59AB4C6F-9E65-4DFD-9E84-EF52D7904884Q44026353-0A4F4E65-9F63-4FC1-9734-62F9E74F88B1Q44876174-BB38A3E2-48C4-49D6-AA2B-57283719FAD8Q46679113-B8E475F6-2113-4B59-8ABE-4179265C5A9AQ48666084-21D7B605-C749-436E-B312-DCDE063B4ABBQ52001288-81B67747-863C-4577-9842-2310349EFA0AQ52933197-D4FEB4DD-90CF-4498-811A-6A2EE3500D15
P2860
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Quality adjusted survival analysis.
@en
type
label
Quality adjusted survival analysis.
@en
prefLabel
Quality adjusted survival analysis.
@en
P2093
P356
P1476
Quality adjusted survival analysis.
@en
P2093
P304
P356
10.1002/SIM.4780091106
P407
P577
1990-11-01T00:00:00Z